<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36389819</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>A GABA-receptor agonist reduces pneumonitis severity, viral load, and death rate in SARS-CoV-2-infected mice.</ArticleTitle><Pagination><StartPage>1007955</StartPage><MedlinePgn>1007955</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1007955</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1007955</ELocationID><Abstract><AbstractText>Gamma-aminobutyric acid (GABA) and GABA-receptors (GABA-Rs) form a major neurotransmitter system in the brain. GABA-Rs are also expressed by 1) cells of the innate and adaptive immune system and act to inhibit their inflammatory activities, and 2) lung epithelial cells and GABA-R agonists/potentiators have been observed to limit acute lung injuries. These biological properties suggest that GABA-R agonists may have potential for treating COVID-19. We previously reported that GABA-R agonist treatments protected mice from severe disease induced by infection with a lethal mouse coronavirus (MHV-1). Because MHV-1 targets different cellular receptors and is biologically distinct from SARS-CoV-2, we sought to test GABA therapy in K18-hACE2 mice which develop severe pneumonitis with high lethality following SARS-CoV-2 infection. We observed that GABA treatment initiated immediately after SARS-CoV-2 infection, or 2 days later near the peak of lung viral load, reduced pneumonitis severity and death rates in K18-hACE2 mice. GABA-treated mice had reduced lung viral loads and displayed shifts in their serum cytokine/chemokine levels that are associated with better outcomes in COVID-19 patients. Thus, GABA-R activation had multiple effects that are also desirable for the treatment of COVID-19. The protective effects of GABA against two very different beta coronaviruses (SARS-CoV-2 and MHV-1) suggest that it may provide a generalizable off-the-shelf therapy to help treat diseases induced by new SARS-CoV-2 variants and novel coronaviruses that evade immune responses and antiviral medications. GABA is inexpensive, safe for human use, and stable at room temperature, making it an attractive candidate for testing in clinical trials. We also discuss the potential of GABA-R agonists for limiting COVID-19-associated neuroinflammation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Tian, Dillion, Henley, Comai and Kaufman.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Jide</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillion</LastName><ForeName>Barbara J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>High Containment Program, University of California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henley</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comai</LastName><ForeName>Lucio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C045927">K-18 conjugate</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GABA-receptors</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">gaba</Keyword><Keyword MajorTopicYN="N">homotaurine</Keyword><Keyword MajorTopicYN="N">long-covid</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>DLK and JT are inventors of GABA-related patents. DLK serves on the Scientific Advisory Board of Diamyd Medical. DLK gifted the Immunotherapeutics Research Fund. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36389819</ArticleId><ArticleId IdType="pmc">PMC9640739</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1007955</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olsen RW, Sieghart W. GABA a receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology (2009) 56(1):141&#x2013;8. doi:&#xa0;10.1016/j.neuropharm.2008.07.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.07.045</ArticleId><ArticleId IdType="pmc">PMC3525320</ArticleId><ArticleId IdType="pubmed">18760291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci (2002) 3(9):728&#x2013;39. doi:&#xa0;10.1038/nrn920</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn920</ArticleId><ArticleId IdType="pubmed">12209121</ArticleId></ArticleIdList></Reference><Reference><Citation>Deidda G, Bozarth IF, Cancedda L. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci (2014) 8:119. doi:&#xa0;10.3389/fncel.2014.00119</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00119</ArticleId><ArticleId IdType="pmc">PMC4033255</ArticleId><ArticleId IdType="pubmed">24904277</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Chau C, Hales TG, Kaufman DL. GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol (1999) 96(1):21&#x2013;8. doi: 10.1016/s0165-5728(98)00264-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-5728(98)00264-</ArticleId><ArticleId IdType="pubmed">10227421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandage AK, Jin Z, Korol SV, Shen Q, Pei Y, Deng Q, et al. . GABA regulates release of inflammatory cytokines from peripheral blood mononuclear cells and CD4(+) T cells and is immunosuppressive in type 1 diabetes. EBioMedicine (2018) 30:283&#x2013;94. doi:&#xa0;10.1016/j.ebiom.2018.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.03.019</ArticleId><ArticleId IdType="pmc">PMC5952354</ArticleId><ArticleId IdType="pubmed">29627388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Middleton B, Lee VS, Park HW, Zhang Z, Kim B, et al. . GABAB-receptor agonist-based immunotherapy for type 1 diabetes in NOD mice. Biomedicines (2021) 9(1). doi:&#xa0;10.3390/biomedicines9010043</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9010043</ArticleId><ArticleId IdType="pmc">PMC7825043</ArticleId><ArticleId IdType="pubmed">33418884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K, et al. . B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature (2021) 599(7885):471&#x2013;6. doi:&#xa0;10.1038/s41586-021-04082-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04082-1</ArticleId><ArticleId IdType="pmc">PMC8599023</ArticleId><ArticleId IdType="pubmed">34732892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandage AK, Barragan A. GABAergic signaling by cells of the immune system: more the rule than the exception. Cell Mol Life Sci (2021) 78(15):5667&#x2013;79. doi:&#xa0;10.1007/s00018-021-03881-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03881-z</ArticleId><ArticleId IdType="pmc">PMC8316187</ArticleId><ArticleId IdType="pubmed">34152447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendu SK, Bhandage A, Jin Z, Birnir B. Different subtypes of GABA-a receptors are expressed in human, mouse and rat T lymphocytes. PLoS One (2012) 7(8):e42959. doi: 10.1371/journal.pone.0042959</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042959</ArticleId><ArticleId IdType="pmc">PMC3424250</ArticleId><ArticleId IdType="pubmed">22927941</ArticleId></ArticleIdList></Reference><Reference><Citation>Januzi L, Poirier JW, Maksoud MJE, Xiang YY, Veldhuizen RAW, Gill SE, et al. . Autocrine GABA signaling distinctively regulates phenotypic activation of mouse pulmonary macrophages. Cell Immunol (2018) 332:7&#x2013;23. doi:&#xa0;10.1016/j.cellimm.2018.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2018.07.001</ArticleId><ArticleId IdType="pubmed">30017085</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Yong J, Dang H, Kaufman DL. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity (2011) 44:465&#x2013;70. doi: 10.3109/08916934.2011.571223</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2011.571223</ArticleId><ArticleId IdType="pmc">PMC5787624</ArticleId><ArticleId IdType="pubmed">21604972</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, et al. . Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 107(6):2580&#x2013;5. doi: 10.1073/pnas.0915139107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0915139107</ArticleId><ArticleId IdType="pmc">PMC2823917</ArticleId><ArticleId IdType="pubmed">20133656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DW, Thompson AJ, Corletto F, Reckless J, Loke JC, Lapaque N, et al. . Anaesthetic impairment of immune function is mediated via GABA(A) receptors. PLoS One (2011) 6(2):e17152. doi:&#xa0;10.1371/journal.pone.0017152</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017152</ArticleId><ArticleId IdType="pmc">PMC3044756</ArticleId><ArticleId IdType="pubmed">21390329</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Garcia MG, Hernandez-Hernandez F, Hernandez-Tellez B, Garcia-Tamayo F. GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6/IL-12 production. J Neuroimmunol (2007) 188(1-2):64&#x2013;8. doi: 10.1016/j.jneuroim.2007.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.05.013</ArticleId><ArticleId IdType="pubmed">17599468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Song M, Kaufman DL. Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis. Sci Rep (2021) 11(1):5402. doi:&#xa0;10.1038/s41598-021-84751-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84751-3</ArticleId><ArticleId IdType="pmc">PMC7940650</ArticleId><ArticleId IdType="pubmed">33686135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandage AK, Friedrich LM, Kanatani S, Jakobsson-Bjorken S, Escrig-Larena JI, Wagner AK, et al. . GABAergic signaling in human and murine NK cells upon challenge with toxoplasma gondii. J Leukoc Biol (2021) 10:617&#x2013;28. doi:&#xa0;10.1002/JLB.3HI0720-431R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3HI0720-431R</ArticleId><ArticleId IdType="pubmed">34028876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JK, Kim YS, Lee HM, Jin HS, Neupane C, Kim S, et al. . GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections. Nat Commun (2018) 9(1):4184. doi:&#xa0;10.1038/s41467-018-06487-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06487-5</ArticleId><ArticleId IdType="pmc">PMC6180030</ArticleId><ArticleId IdType="pubmed">30305619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Dang H, Nguyen AV, Chen Z, Kaufman DL. Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting beta-cell replication in newly diabetic NOD mice. Diabetes (2014) 63(9):3128&#x2013;34. doi:&#xa0;10.2337/db13-1385</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-1385</ArticleId><ArticleId IdType="pmc">PMC4141368</ArticleId><ArticleId IdType="pubmed">25146474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Dang H, O&#x2019;Laco K, Song M, Tiu B-C, Gilles S, et al. . Homotaurine treatment enhances CD4+ and CD8+ treg responses and synergizes with low-dose anti-CD3 to enhance diabetes remission in type 1 diabetic mice. ImmuoHorizons (2019) 3(10):498&#x2013;510. doi:&#xa0;10.4049/immunohorizons.1900019</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.1900019</ArticleId><ArticleId IdType="pmc">PMC6823932</ArticleId><ArticleId IdType="pubmed">31636084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Dang H, Wallner M, Olsen R, Kaufman DL. Homotaurine, a safe blood-brain barrier permeable GABAA-r-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Sci Rep (2018) 8(1):16555. doi:&#xa0;10.1038/s41598-018-32733-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-32733-3</ArticleId><ArticleId IdType="pmc">PMC6224391</ArticleId><ArticleId IdType="pubmed">30410049</ArticleId></ArticleIdList></Reference><Reference><Citation>Prud'homme GJ, Glinka Y, Hasilo C, Paraskevas S, Li X, Wang Q. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. Transplantation (2013) 96(7):616&#x2013;23. doi:&#xa0;10.1097/TP.0b013e31829c24be</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e31829c24be</ArticleId><ArticleId IdType="pubmed">23851932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendu SK, Akesson L, Jin Z, Edlund A, Cilio C, Lernmark A, et al. . Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates. Mol Immunol (2011) 48(4):399&#x2013;407. doi:&#xa0;10.1016/j.molimm.2010.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2010.08.005</ArticleId><ArticleId IdType="pubmed">21112637</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, et al. . GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A (2011) 108(28):11692&#x2013;7. doi:&#xa0;10.1073/pnas.1102715108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102715108</ArticleId><ArticleId IdType="pmc">PMC3136292</ArticleId><ArticleId IdType="pubmed">21709230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Dang HN, Yong J, Chui WS, Dizon MP, Yaw CK, et al. . Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One (2011) 6(9):e25338. doi:&#xa0;10.1371/journal.pone.0025338</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025338</ArticleId><ArticleId IdType="pmc">PMC3178643</ArticleId><ArticleId IdType="pubmed">21966503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol (2004) 173(8):5298&#x2013;304. doi: 10.4049/jimmunol.173.8.5298</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.8.5298</ArticleId><ArticleId IdType="pubmed">15470076</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Tian J, Middleton B, Nguyen CQ, Kaufman DL. GABA administration ameliorates sjogren's syndrome in two different mouse models. Biomedicines (2022) 10(1). doi:&#xa0;10.3390/biomedicines10010129</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010129</ArticleId><ArticleId IdType="pmc">PMC8773584</ArticleId><ArticleId IdType="pubmed">35052808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. . Immunology of COVID-19: Current state of the science. Immunity (2020) 52(6):910&#x2013;41. doi:&#xa0;10.1016/j.immuni.2020.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. . Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature (2020) 584(7821):463&#x2013;9. doi:&#xa0;10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol (2017) 39(5):529&#x2013;39. doi:&#xa0;10.1007/s00281-017-0629-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0629-x</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity (2020) 53(2):248&#x2013;63. doi:&#xa0;10.1016/j.immuni.2020.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.07.005</ArticleId><ArticleId IdType="pmc">PMC7359787</ArticleId><ArticleId IdType="pubmed">32717182</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant RA, Morales-Nebreda L, Markov NS, Swaminathan S, Querrey M, Guzman ER, et al. . Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature (2021) 590(7847):635&#x2013;41. doi:&#xa0;10.1038/s41586-020-03148-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03148-w</ArticleId><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin N, Kolliputi N, Gou D, Weng T, Liu L. A novel function of ionotropic gamma-aminobutyric acid receptors involving alveolar fluid homeostasis. J Biol Chem (2006) 281(47):36012&#x2013;20. doi:&#xa0;10.1074/jbc.M606895200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M606895200</ArticleId><ArticleId IdType="pubmed">17003036</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang YY, Chen X, Li J, Wang S, Faclier G, Macdonald JF, et al. . Isoflurane regulates atypical type-a gamma-aminobutyric acid receptors in alveolar type II epithelial cells. Anesthesiology (2013) 118(5):1065&#x2013;75. doi:&#xa0;10.1097/ALN.0b013e31828e180e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e31828e180e</ArticleId><ArticleId IdType="pubmed">23485993</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang YY, Wang S, Liu M, Hirota JA, Li J, Ju W, et al. . A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. Nat Med (2007) 13(7):862&#x2013;7. doi:&#xa0;10.1038/nm1604</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1604</ArticleId><ArticleId IdType="pubmed">17589520</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrios J, Kho AT, Aven L, Mitchel JA, Park JA, Randell SH, et al. . Pulmonary neuroendocrine cells secrete gamma-aminobutyric acid to induce goblet cell hyperplasia in primate models. Am J Respir Cell Mol Biol (2019) 60(6):687&#x2013;94. doi:&#xa0;10.1165/rcmb.2018-0179OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2018-0179OC</ArticleId><ArticleId IdType="pmc">PMC6543741</ArticleId><ArticleId IdType="pubmed">30571139</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T, Zhang Y, Wang C, Gao J. Propofol reduces acute lung injury by up-regulating gamma-aminobutyric acid type a receptors. Exp Mol Pathol (2019) 110:104295. doi:&#xa0;10.1016/j.yexmp.2019.104295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2019.104295</ArticleId><ArticleId IdType="pubmed">31419406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortis S, Spieth PM, Lu WY, Parotto M, Haitsma JJ, Slutsky AS, et al. . Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury. Intensive Care Med (2012) 38(9):1548&#x2013;55. doi:&#xa0;10.1007/s00134-012-2610-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-012-2610-4</ArticleId><ArticleId IdType="pmc">PMC4896809</ArticleId><ArticleId IdType="pubmed">22711173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chintagari NR, Liu L. GABA receptor ameliorates ventilator-induced lung injury in rats by improving alveolar fluid clearance. Crit Care (2012) 16(2):R55. doi:&#xa0;10.1186/cc11298</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11298</ArticleId><ArticleId IdType="pmc">PMC3681384</ArticleId><ArticleId IdType="pubmed">22480160</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Merchant ML, Ritzenthaler JD, McLeish KR, Lederer ED, Torres-Gonzalez E, et al. . Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators. PLoS One (2015) 10(4):e0121637. doi:&#xa0;10.1371/journal.pone.0121637</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0121637</ArticleId><ArticleId IdType="pmc">PMC4388838</ArticleId><ArticleId IdType="pubmed">25848767</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigtsberger S, Lachmann RA, Leutert AC, Schlapfer M, Booy C, Reyes L, et al. . Sevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injury. Anesthesiology (2009) 111(6):1238&#x2013;48. doi:&#xa0;10.1097/ALN.0b013e3181bdf857</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3181bdf857</ArticleId><ArticleId IdType="pubmed">19934867</ArticleId></ArticleIdList></Reference><Reference><Citation>Faller S, Strosing KM, Ryter SW, Buerkle H, Loop T, Schmidt R, et al. . The volatile anesthetic isoflurane prevents ventilator-induced lung injury via phosphoinositide 3-kinase/Akt signaling in mice. Anesth Analg (2012) 114(4):747&#x2013;56. doi:&#xa0;10.1213/ANE.0b013e31824762f0</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e31824762f0</ArticleId><ArticleId IdType="pubmed">22383671</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi T, Yamamoto K, Ohmoto N, Ohta K, Kobayashi T. Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med (2000) 28(4):1101&#x2013;6. doi:&#xa0;10.1097/00003246-200004000-00032</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200004000-00032</ArticleId><ArticleId IdType="pubmed">10809290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Ju YN, Gao W, Li DM, Guo CC. Desflurane attenuates ventilator-induced lung injury in rats with acute respiratory distress syndrome. BioMed Res Int (2018) 2018:7507314. doi:&#xa0;10.1155/2018/7507314</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7507314</ArticleId><ArticleId IdType="pmc">PMC5833253</ArticleId><ArticleId IdType="pubmed">29670906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud K, Ammar A. Immunomodulatory effects of anesthetics during thoracic surgery. Anesthesiol Res Pract (2011) 2011:317410. doi:&#xa0;10.1155/2011/317410</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/317410</ArticleId><ArticleId IdType="pmc">PMC3205595</ArticleId><ArticleId IdType="pubmed">22110498</ArticleId></ArticleIdList></Reference><Reference><Citation>De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D, et al. . Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology (2009) 110(6):1316&#x2013;26. doi:&#xa0;10.1097/ALN.0b013e3181a10731</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3181a10731</ArticleId><ArticleId IdType="pubmed">19417610</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling T, Kozian A, Kretzschmar M, Huth C, Welte T, Buhling F, et al. . Effects of propofol and desflurane anaesthesia on the alveolar inflammatory response to one-lung ventilation. Br J Anaesth (2007) 99(3):368&#x2013;75. doi:&#xa0;10.1093/bja/aem184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aem184</ArticleId><ArticleId IdType="pubmed">17621602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochiyama T, Li X, Nakayama H, Kage M, Yamane Y, Takamori K, et al. . Effect of propofol on the production of inflammatory cytokines by human polarized macrophages. Mediators Inflammation (2019) 2019:1919538. doi:&#xa0;10.1155/2019/1919538</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1919538</ArticleId><ArticleId IdType="pmc">PMC6441544</ArticleId><ArticleId IdType="pubmed">31007601</ArticleId></ArticleIdList></Reference><Reference><Citation>Forkuo GS, Nieman AN, Kodali R, Zahn NM, Li G, Rashid Roni MS, et al. . A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABAA receptors in the lung. Mol Pharm (2018) 15(5):1766&#x2013;77. doi:&#xa0;10.1021/acs.molpharmaceut.7b01013</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.7b01013</ArticleId><ArticleId IdType="pmc">PMC5954213</ArticleId><ArticleId IdType="pubmed">29578347</ArticleId></ArticleIdList></Reference><Reference><Citation>Boost KA, Leipold T, Scheiermann P, Hoegl S, Sadik CD, Hofstetter C, et al. . Sevoflurane and isoflurane decrease TNF-alpha-induced gene expression in human monocytic THP-1 cells: potential role of intracellular IkappaBalpha regulation. Int J Mol Med (2009) 23(5):665&#x2013;71. doi:&#xa0;10.3892/ijmm_00000178</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm_00000178</ArticleId><ArticleId IdType="pubmed">19360326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredthauer A, Geiger A, Gruber M, Pfaehler SM, Petermichl W, Bitzinger D, et al. . Propofol ameliorates exaggerated human neutrophil activation in a LPS sepsis model. J Inflammation Res (2021) 14:3849&#x2013;62. doi:&#xa0;10.2147/JIR.S314192</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S314192</ArticleId><ArticleId IdType="pmc">PMC8366786</ArticleId><ArticleId IdType="pubmed">34408467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KH, Lu WJ, Wang SH, Fong TH, Chou DS, Chang CC, et al. . Characteristics of endogenous gamma-aminobutyric acid (GABA) in human platelets: functional studies of a novel collagen glycoprotein VI inhibitor. J Mol Med (Berl) (2014) 92(6):603&#x2013;14. doi:&#xa0;10.1007/s00109-014-1140-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-014-1140-7</ArticleId><ArticleId IdType="pubmed">24626935</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoodi M, Peschka M, Schmiedel S, Haddad M, Frye M, Maas C, et al. . Disturbed lipid and amino acid metabolisms in COVID-19 patients. J Mol Med (Berl) (2022) 100(4):555&#x2013;68. doi:&#xa0;10.1007/s00109-022-02177-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-022-02177-4</ArticleId><ArticleId IdType="pmc">PMC8783191</ArticleId><ArticleId IdType="pubmed">35064792</ArticleId></ArticleIdList></Reference><Reference><Citation>Karu N, Kindt A, van Gammeren AJ, Ermens AAM, Harms AC, Portengen L, et al. . Severe COVID-19 is characterised by perturbations in plasma amines correlated with immune response markers, and linked to inflammation and oxidative stress. Metabolites (2022) 12(7). doi:&#xa0;10.3390/metabo12070618</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12070618</ArticleId><ArticleId IdType="pmc">PMC9321395</ArticleId><ArticleId IdType="pubmed">35888742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Middleton B, Kaufman DL. GABAA-receptor agonists limit pneumonitis and death in murine coronavirus-infected mice. Viruses (2021) 13(6). doi:&#xa0;10.3390/v13060966</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13060966</ArticleId><ArticleId IdType="pmc">PMC8224554</ArticleId><ArticleId IdType="pubmed">34071034</ArticleId></ArticleIdList></Reference><Reference><Citation>De Albuquerque N, Baig E, Ma X, Zhang J, He W, Rowe A, et al. . Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. J Virol (2006) 80(21):10382&#x2013;94. doi:&#xa0;10.1128/JVI.00747-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00747-06</ArticleId><ArticleId IdType="pmc">PMC1641767</ArticleId><ArticleId IdType="pubmed">17041219</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Epping LL, Haring JS, et al. . Protective and pathologic roles of the immune response to mouse hepatitis virus type 1: implications for severe acute respiratory syndrome. J Virol (2009) 83(18):9258&#x2013;72. doi:&#xa0;10.1128/JVI.00355-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00355-09</ArticleId><ArticleId IdType="pmc">PMC2738266</ArticleId><ArticleId IdType="pubmed">19570864</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Harty JT, Varga SM. Toll-like receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice. J Virol (2009) 83(17):8946&#x2013;56. doi:&#xa0;10.1128/JVI.01857-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01857-08</ArticleId><ArticleId IdType="pmc">PMC2738158</ArticleId><ArticleId IdType="pubmed">19553337</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanolkar A, Fulton RB, Epping LL, Pham NL, Tifrea D, Varga SM, et al. . T Cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts. J Immunol (2010) 185(2):1132&#x2013;41. doi:&#xa0;10.4049/jimmunol.0902749</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902749</ArticleId><ArticleId IdType="pmc">PMC2897948</ArticleId><ArticleId IdType="pubmed">20554960</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldera-Crespo LA, Paidas MJ, Roy S, Schulman CI, Kenyon NS, Daunert S, et al. . Experimental models of COVID-19. Front Cell Infect Microbiol (2021) 11:792584. doi:&#xa0;10.3389/fcimb.2021.792584</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.792584</ArticleId><ArticleId IdType="pmc">PMC8791197</ArticleId><ArticleId IdType="pubmed">35096645</ArticleId></ArticleIdList></Reference><Reference><Citation>Korner RW, Majjouti M, Alcazar MAA, Mahabir E. Of mice and men: The coronavirus MHV and mouse models as a translational approach to understand SARS-CoV-2. Viruses (2020) 12(8). doi:&#xa0;10.3390/v12080880</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12080880</ArticleId><ArticleId IdType="pmc">PMC7471983</ArticleId><ArticleId IdType="pubmed">32806708</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray PB, Jr., Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, et al. . Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol (2007) 81(2):813&#x2013;21. doi:&#xa0;10.1128/JVI.02012-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02012-06</ArticleId><ArticleId IdType="pmc">PMC1797474</ArticleId><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA, Mann BJ. Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. Am J Trop Med Hyg (2020) 103(3):1215&#x2013;9. doi:&#xa0;10.4269/ajtmh.20-0762</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0762</ArticleId><ArticleId IdType="pmc">PMC7470527</ArticleId><ArticleId IdType="pubmed">32723427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, Garcia-Sastre A, et al. . Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect (2020) 9(1):2433&#x2013;45. doi:&#xa0;10.1080/22221751.2020.1838955</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1838955</ArticleId><ArticleId IdType="pmc">PMC7655046</ArticleId><ArticleId IdType="pubmed">33073694</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden JW, Cline CR, Zeng X, Garrison AR, Carey BD, Mucker EM, et al. . Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight (2020) 5(19). doi:&#xa0;10.1172/jci.insight.142032</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142032</ArticleId><ArticleId IdType="pmc">PMC7566707</ArticleId><ArticleId IdType="pubmed">32841215</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, et al. . SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function. bioRxiv (2020). doi:&#xa0;10.1101/2020.07.09.196188</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.09.196188</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allue-Guardia A, et al. . Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun (2020) 11(1):6122. doi:&#xa0;10.1038/s41467-020-19891-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19891-7</ArticleId><ArticleId IdType="pmc">PMC7705712</ArticleId><ArticleId IdType="pubmed">33257679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Wong LR, Li K, Verma AK, Ortiz ME, Wohlford-Lenane C, et al. . COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature (2021) 589(7843):603&#x2013;7. doi:&#xa0;10.1038/s41586-020-2943-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2943-z</ArticleId><ArticleId IdType="pmc">PMC7855185</ArticleId><ArticleId IdType="pubmed">33166988</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, et al. . SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol (2020) 21(11):1327&#x2013;35. doi:&#xa0;10.1038/s41590-020-0778-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>
NCATS COVID-19 OpenData portal. Available at: https://opendata.ncats.nih.gov/covid19/databrowser.</Citation></Reference><Reference><Citation>Zhang X, Zhang R, Zheng Y, Shen J, Xiao D, Li J, et al. . Expression of gamma-aminobutyric acid receptors on neoplastic growth and prediction of prognosis in non-small cell lung cancer. J Transl Med (2013) 11:102. doi:&#xa0;10.1186/1479-5876-11-102</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-11-102</ArticleId><ArticleId IdType="pmc">PMC3644491</ArticleId><ArticleId IdType="pubmed">23617850</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai D, Fang L, Xia S, Ke W, Wang J, Wu X, et al. . Porcine deltacoronavirus (PDCoV) modulates calcium influx to favor viral replication. Virology (2020) 539:38&#x2013;48. doi:&#xa0;10.1016/j.virol.2019.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2019.10.011</ArticleId><ArticleId IdType="pmc">PMC7112098</ArticleId><ArticleId IdType="pubmed">31670218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraeft SK, Chen DS, Li HP, Chen LB, Lai MM. Mouse hepatitis virus infection induces an early, transient calcium influx in mouse astrocytoma cells. Exp Cell Res (1997) 237(1):55&#x2013;62. doi:&#xa0;10.1006/excr.1997.3768</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.1997.3768</ArticleId><ArticleId IdType="pmc">PMC7133765</ArticleId><ArticleId IdType="pubmed">9417866</ArticleId></ArticleIdList></Reference><Reference><Citation>Loas G, Van de Borne P, Darquennes G, Le Corre P. Association of amlodipine with the risk of in-hospital death in patients with COVID-19 and hypertension: A reanalysis on 184 COVID-19 patients with hypertension. Pharm (Basel) (2022) 15(3). doi:&#xa0;10.3390/ph15030380</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15030380</ArticleId><ArticleId IdType="pmc">PMC8952430</ArticleId><ArticleId IdType="pubmed">35337177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghpopur S, Ghasemnejad-Berenji H, Pashapour S, Ghasemnejad-Berenji M. Using of calcium channel blockers in patients with COVID-19: a magic bullet or a double-edged sword? J Basic Clin Physiol Pharmacol (2021) 33(1):117&#x2013;9. doi:&#xa0;10.1515/jbcpp-2021-0334</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jbcpp-2021-0334</ArticleId><ArticleId IdType="pubmed">34881528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LK, Sun Y, Zeng H, Wang Q, Jiang X, Shang WJ, et al. . Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discovery (2020) 6(1):96. doi:&#xa0;10.1038/s41421-020-00235-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00235-0</ArticleId><ArticleId IdType="pmc">PMC7752915</ArticleId><ArticleId IdType="pubmed">33349633</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. . Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell (2020) 181(5):1036&#x2013;45.e9. doi:&#xa0;10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimabad MN, Kounis NG, Hassanshahi G, Hassanshahi F, Mplani V, Koniari I, et al. . The involvement of CXC motif chemokine ligand 10 (CXCL10) and its related chemokines in the pathogenesis of coronary artery disease and in the COVID-19 vaccination: A narrative review. Vaccines (Basel) (2021) 9(11). doi:&#xa0;10.3390/vaccines9111224</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111224</ArticleId><ArticleId IdType="pmc">PMC8623875</ArticleId><ArticleId IdType="pubmed">34835155</ArticleId></ArticleIdList></Reference><Reference><Citation>Blot M, Jacquier M, Aho Glele LS, Beltramo G, Nguyen M, Bonniaud P, et al. . CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS. Crit Care (2020) 24(1):632. doi:&#xa0;10.1186/s13054-020-03328-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03328-0</ArticleId><ArticleId IdType="pmc">PMC7604548</ArticleId><ArticleId IdType="pubmed">33138839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran R, McReynolds C, Yang J, Hammock BD, Ikram A, Ali A, et al. . Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. PloS One (2021) 16(7):e0254367. doi:&#xa0;10.1371/journal.pone.0254367</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254367</ArticleId><ArticleId IdType="pmc">PMC8270414</ArticleId><ArticleId IdType="pubmed">34242356</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JS, Kim JY, Kim MC, Park SY, Kim BN, Bae S, et al. . Factors of severity in patients with COVID-19: Cytokine/Chemokine concentrations, viral load, and antibody responses. Am J Trop Med Hyg (2020) 103(6):2412&#x2013;8. doi:&#xa0;10.4269/ajtmh.20-1110</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-1110</ArticleId><ArticleId IdType="pmc">PMC7695090</ArticleId><ArticleId IdType="pubmed">33124544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy AS, Vishwakarma S, Trimbake D, Gurav YK, Potdar VA, Mokashi ND, et al. . Pro-inflammatory CXCL-10, TNF-alpha, IL-1beta, and IL-6: biomarkers of SARS-CoV-2 infection. Arch Virol (2021) 166(12):3301&#x2013;10. doi:&#xa0;10.1007/s00705-021-05247-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-021-05247-z</ArticleId><ArticleId IdType="pmc">PMC8459145</ArticleId><ArticleId IdType="pubmed">34554303</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. . CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev (2011) 22(3):121&#x2013;30. doi:&#xa0;10.1016/j.cytogfr.2011.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2011.06.001</ArticleId><ArticleId IdType="pmc">PMC3203691</ArticleId><ArticleId IdType="pubmed">21802343</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. . An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight (2021) 6(1). doi:&#xa0;10.1172/jci.insight.144455</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.144455</ArticleId><ArticleId IdType="pmc">PMC7821609</ArticleId><ArticleId IdType="pubmed">33232303</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect (2020) 9(1):1123&#x2013;30. doi:&#xa0;10.1080/22221751.2020.1770129</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. . Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight (2020) 5(13). doi:&#xa0;10.1172/jci.insight.139834</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.139834</ArticleId><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. . Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature (2021) 595(7868):565&#x2013;71. doi:&#xa0;10.1038/s41586-021-03710-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. . SARS-CoV-2 is associated with changes in brain structure in UK biobank. Nature (2022) 604(7907):697&#x2013;707. doi:&#xa0;10.1038/s41586-022-04569-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere JJ, Serafini RA, Pryce KD, Zazhytska M, Oishi K, Golynker I, et al. . SARS-CoV-2 infection results in lasting and systemic perturbations post recovery. Biorxiv (2022). doi:&#xa0;10.1101/2022.01.18.476786</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.18.476786</ArticleId><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F, Carregari CC, Veras FP, Henrique Vendramini P, Valen&#xe7;a AGF, Antunes ASLM, et al. . Morphological, cellular and molecular basis of brain infection in COVID-19 patients. MedRxiv (2020) 16. doi:&#xa0;10.1101/2020.10.09.20207464</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.09.20207464</ArticleId><ArticleId IdType="pmc">PMC9436354</ArticleId><ArticleId IdType="pubmed">35951647</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar J, Naas A, Fallmar D, Cunningham JL, Klang A, Ashton NJ, et al. . Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol (2021) 28(10):3324&#x2013;31. doi:&#xa0;10.1111/ene.14703</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14703</ArticleId><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, Nilsson S, et al. . Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology (2020) 95(12):e1754&#x2013;e9. doi:&#xa0;10.1212/WNL.0000000000010111</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010111</ArticleId><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. . Microvascular injury in the brains of patients with covid-19. N Engl J Med (2021) 384(5):481&#x2013;3. doi:&#xa0;10.1056/NEJMc2033369</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A, Mohamed MS, Moulin TC, Schioth HB. Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms. J Neuroimmunol (2021) 358:577658. doi:&#xa0;10.1016/j.jneuroim.2021.577658</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577658</ArticleId><ArticleId IdType="pmc">PMC8272134</ArticleId><ArticleId IdType="pubmed">34304141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Schwab C, McGeer PL. Astrocytes are GABAergic cells that modulate microglial activity. Glia (2011) 59(1):152&#x2013;65. doi:&#xa0;10.1002/glia.21087</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21087</ArticleId><ArticleId IdType="pubmed">21046567</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano S, Aguera L, Aguilar M, Olazaran J. A review on tramiprosate (Homotaurine) in alzheimer's disease and other neurocognitive disorders. Front Neurol (2020) 11:614. doi:&#xa0;10.3389/fneur.2020.00614</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00614</ArticleId><ArticleId IdType="pmc">PMC7358344</ArticleId><ArticleId IdType="pubmed">32733362</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. . Tramiprosate in mild-to-moderate alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the alphase study). Arch Med Sci (2010) 7(1):102&#x2013;11. doi: 10.5114/aoms.2011.20612</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2011.20612</ArticleId><ArticleId IdType="pmc">PMC3258678</ArticleId><ArticleId IdType="pubmed">22291741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsolaki M. Future strategies of management of alzheimer's disease. the role of homotaurine. Hell J Nucl Med (2019) 22 Suppl:82&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">30877726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. . Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: exploratory analyses of the MRI sub-group of the alphase study. J Nutr Health Aging (2009) 13(6):550&#x2013;7. doi: 10.1007/s12603-009-0106-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-009-0106-x</ArticleId><ArticleId IdType="pubmed">19536424</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss&#xf9; P, Salani F, Ciaramella A, Sacchinelli E, Mosca A, Banaj N, et al. . Anti-inflammatory effects of homotaurine in patients with amnestic mild cognitive impairment. Front Aging Neurosci (2018) 2 10:285. doi: 10.3389/fnagi.2018.00285</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00285</ArticleId><ArticleId IdType="pmc">PMC6230970</ArticleId><ArticleId IdType="pubmed">30455639</ArticleId></ArticleIdList></Reference><Reference><Citation>Oketch-Rabah HA, Madden EF, Roe AL, Betz JM. United states pharmacopeia (USP) safety review of gamma-aminobutyric acid (GABA). Nutrients (2021) 13(8). doi:&#xa0;10.3390/nu13082742</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13082742</ArticleId><ArticleId IdType="pmc">PMC8399837</ArticleId><ArticleId IdType="pubmed">34444905</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm (2016) 7(2):27&#x2013;31. doi:&#xa0;10.4103/0976-0105.177703</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-0105.177703</ArticleId><ArticleId IdType="pmc">PMC4804402</ArticleId><ArticleId IdType="pubmed">27057123</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg (1938) 27:493&#x2013;7.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>